ArticleCurrent drug delivery2026
Advancements in 3D Printing and Nanomaterials for Personalized Drug Delivery.
Article in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3D printing, also known as additive manufacturing, has transformed drug delivery by enabling the development of complex, patient-specific dosage forms and implantable systems tailored to individual therapeutic needs. This review explores the convergence of 3D printing technologies with nanomaterials in the fabrication of advanced drug delivery systems and biomedical implants. Key 3D printing techniques, including Fused Deposition Modeling (FDM), Stereolithography (SLA), Direct Energy Deposition (DED), and electrospinning, are discussed alongside their material compatibilities, such as polymers, metals, ceramics, and composites. Nanomaterials-like dendrimers, liposomes, polymeric nanoparticles, carbon nanotubes, and exosomes-are critically examined for their roles in enhancing drug stability, targeted delivery, and controlled release. The paper highlights innovative drug delivery strategies, including polypills, gastro-floating tablets, and compartmentalized dosage systems, enabled by precise 3D printing. Additionally, recent advancements in 3D-printed drugeluting implants for localized therapy in cancer and infectious diseases are presented. These systems demonstrate prolonged release profiles, biocompatibility, and mechanical properties resembling those of human tissue. Despite scaling and regulatory challenges, the future of this technology lies in the integration of smart materials, surface-modified nanoparticles, and AI-assisted design, paving the way for decentralized, personalized, and sustainable medical solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.